Judge Questions Fees In Abbott Investors' $40M Formula Deal
An Illinois federal judge on Thursday granted final approval to most of Abbott Laboratories' $40 million deal to resolve shareholder claims over its management of a 2022 infant formula crisis, but...To view the full article, register now.
Already a subscriber? Click here to view full article